Alnylam Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
UBS Raises Alnylam Pharmaceuticals' Price Target to $308 From $288, Buy Rating Maintained
Alnylam Pharmaceuticals Analyst Ratings
Scotiabank Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $83
Goldman Sachs Upgrades Alnylam Pharmaceuticals(ALNY.US) to Buy Rating, Raises Target Price to $370
Buy Rating Affirmed for Alnylam Pharmaceuticals on Strong Amvuttra Trial Results and Robust Market Potential
Scotiabank Reaffirms Their Buy Rating on Bio-Techne (TECH)
BofA Securities Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $51
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Avidity Biosciences (RNA) and Veeva Systems (VEEV)
Promising Phase 1/2 Results for Avidity Biosciences Reinforce Buy Rating With New Price Objective
RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $181 Price Target
Sarepta Therapeutics Analyst Ratings
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $181
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $56
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Natera (NTRA) and Disc Medicine (IRON)
Bio-Techne Analyst Ratings
Leerink Partners Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $64
Morgan Stanley Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $132
Benchmark Co. Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $95